RT Journal Article
SR Electronic
T1 Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA937
DO 10.1183/1393003.congress-2017.PA937
VO 50
IS suppl 61
A1 Nicolas Roche
A1 Hicham Benhaddi
A1 Marianka van der Tol
A1 Jonathan Chambers
A1 Job FM van Boven
A1 Leif Bjermer
A1 Marc miravitlles
A1 David Price
A1 Jaco Voorham
YR 2017
UL http://erj.ersjournals.com/content/50/suppl_61/PA937.abstract
AB Background: DuoResp Spiromax is an inhaled corticosteroid (ICS)/long-acting β2-agonist fixed-dose combination inhaler, designed to reduce common inhaler errors and enhance usability (reliable dosing and good lung deposition) for patients (pts) with asthma/COPD.Aims/Objectives: To evaluate the non-inferiority of DuoResp after changing from Symbicort, vs staying on Symbicort (pts achieving disease control [based on Risk Domain Control, RDC, algorithm]; exacerbation rate; short-acting β2-agonists (SABA) use; and treatment stability [achieved RDC; no treatment boost]).Methods: Asthma/COPD pts who changed from Symbicort to DuoResp were matched (3:1) with pts staying on Symbicort. Data were from the Optimum Patient Care Research Database and Clinical Practice Research Datalink. To achieve RDC, pts must not have had respiratory related hospitalization, accident/emergency attendance, exacerbations, and oral CS or antibiotic courses.Results: Compared with 1091 pts (asthma 743; COPD 348) staying on Symbicort, 385 matched pts (asthma 253; COPD 132) who changed to DuoResp had non-inferiority in RDC (adjusted difference +6.6% [95% CI, -0.3–13.5]). In asthma pts, DuoResp (vs Symbicort) resulted in fewer exacerbations (adjusted rate ratio [RR] 0.76; p=0.044); lower odds of being in a high SABA dose category (OR 0.71; p=0.034); used fewer SABA inhalers (RR 0.92; p=0.019) and higher odds of achieving treatment stability (adjusted odds ratio 1.44; p=0.037). No significant differences were found in COPD pts.Conclusions: In real-life asthma/COPD patients, DuoResp was non-inferior (in RDC) to Symbicort. In asthma pts, DuoResp was associated with better health outcomes.